Akeso マネジメント

マネジメント基準チェック /34

Akesoの CEO はMichelle Xiaで、 Mar2012年に任命され、の在任期間は 12.83年です。の年間総報酬はCN¥ 6.52Mで、 67%給与と33%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の8.53%を直接所有しており、その価値はHK$ 4.65B 。経営陣と取締役会の平均在任期間はそれぞれ2.2年と5.2年です。

主要情報

Michelle Xia

最高経営責任者

CN¥6.5m

報酬総額

CEO給与比率	67.0%
CEO在任期間	12.8yrs
CEOの所有権	8.5%
経営陣の平均在職期間	2.2yrs
取締役会の平均在任期間	5.2yrs

経営陣の近況

Akeso, Inc.'s (HKG:9926) CEO Compensation Is Looking A Bit Stretched At The Moment

Jun 24

Recent updates

Optimistic Investors Push Akeso, Inc. (HKG:9926) Shares Up 27% But Growth Is Lacking

Sep 09

Akeso, Inc. Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Aug 30

Akeso, Inc.'s (HKG:9926) CEO Compensation Is Looking A Bit Stretched At The Moment

Jun 24

Little Excitement Around Akeso, Inc.'s (HKG:9926) Revenues As Shares Take 25% Pounding

Jun 19

Results: Akeso, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Mar 20

CEO報酬分析

Akeso の収益と比較して、Michelle Xia の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	-CN¥735m
Mar 31 2024	n/a	n/a	CN¥646m
Dec 31 2023	CN¥7m	CN¥4m	CN¥2b
Sep 30 2023	n/a	n/a	CN¥2b
Jun 30 2023	n/a	n/a	CN¥2b
Mar 31 2023	n/a	n/a	CN¥409m
Dec 31 2022	CN¥5m	CN¥4m	-CN¥1b
Sep 30 2022	n/a	n/a	-CN¥1b
Jun 30 2022	n/a	n/a	-CN¥1b
Mar 31 2022	n/a	n/a	-CN¥1b
Dec 31 2021	CN¥7m	CN¥4m	-CN¥1b
Sep 30 2021	n/a	n/a	-CN¥1b
Jun 30 2021	n/a	n/a	-CN¥929m
Mar 31 2021	n/a	n/a	-CN¥983m
Dec 31 2020	CN¥7m	CN¥3m	-CN¥1b
Sep 30 2020	n/a	n/a	-CN¥870m
Jun 30 2020	n/a	n/a	-CN¥703m
Mar 31 2020	n/a	n/a	-CN¥492m
Dec 31 2019	CN¥2m	CN¥1m	-CN¥282m

報酬と市場: Michelleの総報酬 ($USD 893.78K ) は、 Hong Kong市場 ($USD 708.77K ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Michelleの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Michelle Xia (57 yo)

12.8yrs

在職期間

CN¥6,524,000

報酬

Dr. Yu Xia, Ph D., also known as Michelle, is CEO & President of Akeso Biopharma, Inc. Dr. Xia is Founder of Akeso, Inc. Dr. Xia is CEO, President & Chairwoman of Akeso, Inc. from March 19, 2012. She has b...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Yu Xia	Founder	12.8yrs	CN¥6.52m	8.53% HK$ 4.6b
Baiyong Li	Co-Founder	12.8yrs	CN¥5.02m	5.65% HK$ 3.1b
Zhongmin Wang	Co-Founder	no data	CN¥3.60m	4.81% HK$ 2.6b
Yu Xia	Senior Vice President	less than a year	CN¥33.65m	データなし
Peng Zhang	Co-Founder	no data	データなし	データなし
Bing Wang	Chief Financial Officer	less than a year	データなし	データなし
Xinfeng Zhang	Senior Vice President	4.5yrs	データなし	データなし
Mingxiu Hu	Senior Vice President	3yrs	データなし	データなし
Charlie Zhang	Senior Vice President	2yrs	データなし	データなし
Jing Min	Senior Vice President	2yrs	データなし	データなし
Yong Guo	Senior VP & Chief Commercial Officer	less than a year	データなし	データなし
Wai Yan Leung	Company Secretary	2.4yrs	データなし	データなし

2.2yrs

平均在職期間

55yo

平均年齢

経験豊富な経営陣: 9926の経営陣は経験豊富であると考えられます ( 2.2年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Yu Xia	Founder	12.8yrs	CN¥6.52m	8.53% HK$ 4.6b
Baiyong Li	Co-Founder	5.2yrs	CN¥5.02m	5.65% HK$ 3.1b
Zhongmin Wang	Co-Founder	5.2yrs	CN¥3.60m	4.81% HK$ 2.6b
Peng Zhang	Co-Founder	less than a year	データなし	データなし
Bo Tan	Independent Non-Executive Director	no data	CN¥317.00k	データなし
Ronggang Xie	Non-Executive Director	4.4yrs	データなし	データなし
Yan Xu	Independent Non-Executive Director	no data	CN¥319.00k	データなし
Junwen Zeng	Independent Non-Executive Director	no data	CN¥317.00k	データなし

5.2yrs

平均在職期間

55yo

平均年齢

経験豊富なボード: 9926の取締役会は経験豊富であると考えられます ( 5.2年の平均在任期間)。

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2025/01/02 15:18
終値	2025/01/02 00:00
収益	2024/06/30
年間収益	2023/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を例とし、非米国証券については同等の規制書式と情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Akeso, Inc. 19 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。38

アナリスト	機関
Yonglin Yan	BOCI Research Ltd.
Sharon Shi	BOCI Research Ltd.
Jiangqiao Tong	BOCI Research Ltd.

Akeso マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Co-Founder recently sold HK$214m worth of stock

Akeso, Inc. Announces Appointment of Bing C. Wang as Chief Financial Officer

Akeso, Inc. Announces Change of Directors

Akeso, Inc.'s (HKG:9926) CEO Compensation Is Looking A Bit Stretched At The Moment

Akeso, Inc., Annual General Meeting, Jun 30, 2024

Founder recently sold HK$96m worth of stock

Recent updates

Co-Founder recently sold HK$214m worth of stock

Akeso Announces the Inclusion in China's National Reimbursement Drug List of Cadonilimab and Ivonescimab

Akeso, Inc.'s Penpulimab Combination Therapy for First-Line Treatment of Hepatocellular Carcinoma Accepted by NMPA

Akeso, Inc. Publishes Mechanism of Action for CLDN18.2/CD47 Bispecific Antibody AK132 for the First Time at SITC Annual Meeting

Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combined with Ligufalimab (CD47) for First-Line Treatment of Head and Neck Squamous Cell Carcinoma (HNSCC), Compared to Pembrolizumab

Akeso, Inc. has completed a Follow-on Equity Offering in the amount of HKD 1.942576 billion.

Akeso Biopharma Announces Positive Results in Progression-Free Survival (PFS) and Overall Survival (OS) from Its Phase 3 Clinical Study

First half 2024 earnings released: CN¥0.28 loss per share (vs CN¥3.02 profit in 1H 2023)

Akeso's Cadonilimab Receives Second Indication Approval from NMPA for First-Line Treatment of Gastric/GEJ Cancer in All-Comers Population

Akeso, Inc. Secures Approval from China’s National Medical Products Administration for Ebronucimab, Expanding Treatment Options for Hypercholesterolemia

Akeso's Ivonescimab Plus Chemo in First-Line Triple-negative Breast Cancer Showed Promising Preliminary Efficacy and Good Safety At ESMO 2024

Optimistic Investors Push Akeso, Inc. (HKG:9926) Shares Up 27% But Growth Is Lacking

Consensus EPS estimates upgraded to CN¥0.43 loss

Akeso, Inc. Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

First half 2024 earnings released: CN¥0.28 loss per share (vs CN¥3.02 profit in 1H 2023)

Akeso, Inc. to Report Q2, 2024 Results on Aug 28, 2024

Akeso, Inc. Announces Ivonescimab (Pd-1/Vegf) Received Priority Review from China's Nmpa for First-Line Treatment of Pd-L1 Positive Nsclc

Akeso, Inc. Announces That the First Patient Enrolled in the US Phase 2 Combination Therapy of it's Ligufalimab with Azacitidine for Myelodysplastic Syndrome

Akeso's Sbla for Ivonescimab in 1L Treatment of Pd-L1 Positive Nsclc Accepted by NMPA

Akeso, Inc. Announces Appointment of Bing C. Wang as Chief Financial Officer

New major risk - Share price stability

Akeso, Inc. Announces Change of Directors

Akeso, Inc.'s (HKG:9926) CEO Compensation Is Looking A Bit Stretched At The Moment

Little Excitement Around Akeso, Inc.'s (HKG:9926) Revenues As Shares Take 25% Pounding

Akeso, Inc., Annual General Meeting, Jun 30, 2024

Akeso, Inc. Announces Phase III Clinical Trial, Harmoni-2 or AK112-303 Met Its Primary Endpoint of Progression-Free Survival

Are Investors Undervaluing Akeso, Inc. (HKG:9926) By 43%?

New minor risk - Share price stability

Akeso, Inc. Receives NMPA's Marketing Approval in China for Ivonescimab Injection

Investor sentiment deteriorates as stock falls 24%

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient Growth At Akeso, Inc. (HKG:9926) Hampers Share Price

National Medical Products Administration Accepted the Supplemental New Drug Application by Akeso, Inc. for (Cadonilimab, Pd-1/Ctla-4) as First-Line Treatment for Cervical Cancer

New minor risk - Shareholder dilution

Akeso, Inc. has completed a Follow-on Equity Offering in the amount of HKD 1.18172 billion.

We Think Akeso's (HKG:9926) Robust Earnings Are Conservative

Akeso, Inc. has filed a Follow-on Equity Offering in the amount of HKD 1.18172 billion.

Akeso, Inc. has filed a Follow-on Equity Offering in the amount of HKD 1.18172 billion.

Results: Akeso, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improves as stock rises 15%

Akeso, Inc. to Report Fiscal Year 2023 Results on Mar 18, 2024

Akeso Announces the First Patient Dosed in Phase III Trial of Cadonilimab(PD-1/CTLA-4) Combined with Chemotherapy versus Tislelizumab Combined with Chemotherapy in First-Line Treatment of PD-L1 negative NSCLC

Akeso Presents Promising Results of Cadonilimab and Lenvatinib in Combination with TACE in uHCC at 2024 ASCO GI

Akeso, Inc. Announces Innovative Clinical Development Roadmap

Akeso, Inc. Announces National Medical Products Administration Accepts the Supplemental New Drug Application for Kai Tan Ni (Cadonilimab, PD-1/CTLA-4) in Combination with Chemotherapy as First-Line Treatment for Gastric Cancer

Akeso, Inc. Publishes Results from CD47 Antibody Ligufalimab in Combination with Azacitidine for Newly Diagnosed Higher-Risk Myelodysplastic Syndrome and Treatment-nave Acute Myeloid Leukemia at ASH 2023

Akeso Publishes Results from Three Investigator-Initiated Trials

Founder recently sold HK$96m worth of stock

Akeso (9926. Hk) Announces AK104-303 Phase III Trial Meets One of its Primary Endpoints of Progression-Free Survival (PFS) for First-Line Treatment of Recurrent/Metastatic Cervical Cancer

Akeso (9926. Hk) Announces AK104-303 Phase III Trial Meets One of its Primary Endpoints of Progression-Free Survival (PFS) for First-Line Treatment of Recurrent/Metastatic Cervical Cancer

Akeso, Inc. Announces AK104-303, A Phase III Trial of Cadonilimab Reached Progression-Free-Survival Primary Endpoint At Interim Analysis for First Line Treatment of Cervical Cancer

Akeso's Cadonilimab (PD-1/CTLA-4) Phase III Trial Meets Primary Endpoint at Interim Analysis Demonstrating Strong Overall Survival Benefit as First-line Treatment in All-comer Patients with Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC)

Co-Founder recently sold HK$4.4m worth of stock

Investor sentiment improves as stock rises 17%

Akeso Announces Results of Phase Ib Clinical Trial for PD-1/VEGF Bispecific Antibody

Akeso Announces the Publication of the Phase 1a/1b First-In-Human Study

Akeso, Inc. Announces Clinical Results from Cadonilimab in Patients with Advanced Solid Tumours (COMPASSION-03/AK104-201)

Akeso, Inc. Announces FDA Clearance of IND for CD47 Monoclonal Antibody (AK117) in Combination with Azacitidine in Myelodysplastic Syndromes

First half 2023 earnings released: EPS: CN¥3.02 (vs CN¥0.77 loss in 1H 2022)

New major risk - Revenue and earnings growth

Akeso Inc. Announces Completion of Patient Enrollment in Phase 3 Trial of Ivonescimab (PD-1/VEGF) versus Pembrolizumab in First-Line PD-L1 Positive Advanced NSCLC

Akeso, Inc. Announces the National Medical Products Administration Accepts the New Drug Application for the Ebdarokimab Injection (IL-12/IL-23 Monoclonal Antibody, AK101)

Akeso Inc. Announces First Patient Dosed in Phase 3 Trial of Ivonescimab versus Tislelizumab for First-Line Treatment of Squamous NSCLC

Akeso, Inc. to Report First Half, 2023 Results on Aug 29, 2023

New minor risk - Share price stability

Akeso, Inc., Annual General Meeting, Jun 28, 2023

NMPA Accepts Akeso's Ebronucimab (PCSK9 ) Marketing Application in Two Cardiovascular Indications

Full year 2022 earnings: EPS and revenues miss analyst expectations

マネジメント基準チェック /34